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Although reference to a disease causing anaemia in children 
can be found in ancient Greek and Italian writings I , the first 
clinical description of thalassaemia as a separate entity, was 
done by Cooley and Lee in 1925,2 Since then b-thalassaemia 
has also been known as Cooley's anaemia. The term 
' thalassaemia' was in fact coined by Whipple and Bradford3 
in 1932, in their paper on the pathology of the disease. 
Thalassaemia is derived from the Greek word 
Qalassa (Thalassa) meaning 'the sea'. 
It has been generally accepted that the high incidence of 
thalassaemia and the common haemoglobin variants, Hb 
S, Hb E and HB C, in certain areas of the world is the result 
of selective pressures of Plasmodiumfalciparum malaria.4,5 
As can be seen in figure I , the distribution of these disorders 
follow quite closely the distribution of P falciparum. There 
is good evidence to believe that carriers of one mutated 
gene had a higher reproductive fitness in malarial areas as 
compared to nonnal individuals, possibly due to an inability 
of the intracellular parasite to complete its life cycle. 
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Human Haemoglobins - Structure 
Human haemoglobins are tetramers of two a-globins, i.e . 
S or a, and two non-a-globins, i.e. e, Gy, Ay, 8, or ~ each 
associated with a haem group. The haem group is formed 
by an iron atom surrounded by a porphyrin ring. The genes 
that encode for the glob ins are arranged 5' to 3' in the same 
order in which they are sequentially expressed during 
development. Thus the a-globin gene cluster, spanning a 
region of around 50 kilobases (Kb) on the short arm of 
chromosome 16, contains the embryonic S gene and two a 
genes - 0.2 and a I, together with a number of non-functional 
pseudo-genes. 
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Figure 2. Globin chain synthesis at different stages 
of foetal maturation (Source: Weatherall DJ and 
Clegg JB , The Thalassaemia Syndromes2) 
The non-a-gene cluster, spanning a region of around 90Kb 
on the short arm of chromosomes 11 , comprises, from 5' 
to 3', the embryonic e-gene, two foetal genes, Gy and Ay, 
and the adult 8 and ~ genes. 
Molecular structure of globin genes 
Being only around 2 Kb long, globin genes are relatively 
small, in contrast to other genes (blood coagulation Factor 
VII gene ~ 13Kb; human dystrophlll gene ~2 megabases 
Mb). The relatively small size facilitated the identification 
and characterisation of mutations leading to thalassaemia 
and other haemoglobin variants . 
In thalassaemia, there is a reduction of one of the globin 
chains due to mutations or deletions affecting DNA 
transcription or translation. a -thalassaemia (affecting 0.-
chain production) and ~-thalassaemia (affecting ~-chain 
production) are common and clinically important. 
Whilst the majority of ~-thalassaemia conditions are due 
to point mutations involving one or two nucleotides, 0.-
thalassaemia is commonly due to large deletions involving 
the whole gene. Thalassemia mutations and deletions are 
relatively population specific and Malta is no exception. 
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Around 72% of the ~-thalassaemia 
cases are due to the relatively mild 
IVS 1-6T->C mutation (i.e. a Cytosine 
to Thymine substitution in the 6th 
nucleotide of the first intron 
sequencing).6 This mutation decreases 
the efficiency of nonnal splicing (to 
about 30% of normal), resulting in an 
increase in the utilisation of the 
alternative splice sites and a 
prematurely telminated protein. 
Three other mutations, codon 39 C-
>T (insertion of a premature stop 
codon), the IVS-I-110 G->A 
(production of a new acceptor splice 
site in the first intron) and the IVS-II-
1 G->A (abolition of the splice site), 
make up the remaining 28%. In the 
case of ·-thalassaemia, a 3.7 Kb 
deletion (basically this deletion reduces 
the number of a gene copies to 1 from 
the normal 2 genes per chromosome 
16), is the only a gene deletion 
discovered amongst the Maltese 
population. 
From the Imowledge ofthe molecular 
pathology, it is clear that the major 
problem in thalassaemia is a disbalance 
between the a and ~ glob ins that are 
an integral part ofthe heamoglobin 
molecule. Thus in ~-thalassaemia, 
there is a relatively higher level of a 
globin in relationship to ~-globin and 
vice versa in a -thalassaemia. The 
unpaired, excess globin chains either 
form unstable tetramers (~ chains -
HbH and y chains - HbBarts) or else 
the a chains bind to the erythrocyte 
membranes causing membrane 
damage. In both cases, apart from 
inefficient erythropoiesis there is also 
increased intra-medullary haemolysis. 
Whilst thalassaemia carriers (i.e. 
carrying one mutated allele in the case 
of ~-thalassaemia and up to 2 
mutated/deleted alleles in the case of 
a-thalassaemia) are usually 
asymptomatic, they have a slightly 
lowered haemoglobin level (10-12g/dl) 
and microcytosis (a MCV lower than 
80ft and a MCH lower than 26pg) with 
a high Hb A2 (higher than 3.5%) in · 
the case of ~ thalassaemia carriers. 
The identification of thalassaemia 
carriers is further complicated by 
concurrent presence of iron deficiency. 
In the case of ~-thalassaemia, the 
presence of mutations causing mild 
disease, or concurrent presence of a-
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thalassaemia or 8-~, thalassaemia 
(deleterious mutations in both the 8 
and ~ genes) can further complicate 
its diagnosis. 
Thalassaemia Major 
Thalassaemia major can be divided 
into aD or ~D and a + or ~+ depending 
on the amount of the respective 
residual globin chain production. 
Whilst aD and ~D thalassaemias are 
present with very severe anaemia, in 
a + and ~+ thalassaemias the picture is 
more varied. a + thalassaemia can be 
divided into two distinct groups: 
1. Individuals that inherit 
Thalassemia 3 normal a -genes (-
a/aa). These individuals are referred 
to clinically as silent carriers of a-
thalassemia or a-thalassemia-2 trait. 
The affected individuals exhibit no 
clinical abnormality and usually have 
mild reductions in red cell mean 
corpuscular volume (MCV) and mean 
corpuscular hemoglobin (MCH). 
2. The inheritance of 2 normal alpha 
genes either due to heterozygosity for 
alpha (0) thalassemia (aa/--) or 
homozygosity for alpha (+) 
thalassemia (-a/-a) results in the 
development of a -thalassemia minor 
or a-thalassemia-l trait. Similarly to 
a-thalassemia-2, the affected 
individuals are clinically noonal with 
minimal anaemia and reduced MCV 
and MCH. 
3. HbH disease or the inheritance of one 
nonnal alpha gene (-a/--), is the result of 
ablmdant fonnation ofhemoglobin H 
composed of tetramers of excess beta 
chains. The affected individuals have 
moderate to severe lifelong haemolytic 
anemia, modest degrees of ineffective 
etyiliropoiesis, splenomegaly and variable 
bony changes. 
The clinical picture of W 
thalassaemia is more varied as it 
depends on the inherited mutation and 
other genetic (and probably 
environmental) factors. The clinical 
picture can range from a severe to 
moderate anaemia (Hb levels of 5 to 
8 g/dl) to very mild anaemia (9-1 Og/dl). 
Clinical Management of 
Thalassaemia 
The classical management of 
thalassemia is based on an adequate 
transfusion regime and proper iron 
chelation. The transfusion regime 
(usually every 4-6 weeks) is aimed at 
ensuring that the mean haemoglobin 
level is arolmd 9-1 Og/dl, thus reducing 
the lifelong complications associated 
with severe, chronic anaemia. Coupled 
with the transfusions, these individuals 
require adequate iron chelation, to 
reduce iron overload. Up to now, this 
was achieved through the daily, 
subcutaneous injection of 
deferoxamine administered through a 
syringe pump but newer, oral chelators 
have been developed and are presently 
being introduced into the market. 
These oral chelators are offering both 
a reduction in the discomfort from the 
subcutaneous injection as well as 
generally improving the compliance 
and thus reducing iron overload 
complications. 
In addition to transfusion and 
chelation, splenectomy has the 
potential of reducing the transfusion 
requirement and is usually performed 
just before puberty. Furthermore, bone 
marrow transplant, when appropriate 
and where a donor is available, offers 
a cure, as opposed to treatment, for 
thalassaemia major individuals.8J 
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